Be the ﬁrst to know about our upcoming events! Latest events & seminars straight to your email
During pregnancy, if the mother suffers from organ damage, the baby in the womb sends stem cells to repair the damaged organ
Dawe GS, Tan XW, Xiao Z-C. Cell Migration from Baby to Mother. Cell Adhesion & Migration. 2007;1(1):19-27.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2633676/ Accessed July 26, 2017
The probability of finding a donor stem cell source through a public bank is low. Banking cord blood with a family bank increases the chances of having a matched unit available.
Beatty PG, Boucher KM, Mori M, Milford EL. The probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Hum Immunol. 2000;61(8):834-840.
Graft versus Host Disease (GVHD) is a common side effect of any transplant when the immune cells of the recipient’s body do not recognize the donor’s cells and start attacking them, thus leading to failure of the transplant.
Lee, Stephanie J.; Vogelsang, Georgia; Flowers, Mary E.D. (2003). “Chronic graft-versus-host disease”. Biology of Blood and Marrow Transplantation. 9 (4): 215–33
GVHD is broadly categorized into two types, the acute and chronic where its symptoms can range from modest to serious.
www.lls.org/…/f-73147405621_AvrIWIiW_bloodmarrowstemcelltransplantation.pdf. Accessed September 7, 2017
Cord blood is currently used in the treatment of around 80 diseases,
Data on file. Retrieved June 13, 2017 from ViaCord.com .PerkinElmer, Inc. Most of the diseases on this list are inherited genetic diseases. Typically, these treatments require a donor transplant, such as from a sibling. If your child needs a donor, a family member is always the first-choice source. Treatments for cancers like neuroblastoma can use a child’s own cord blood. Although the potential use of newborn stem cells is expanding rapidly, the odds a family member without a defined risk will need to use their child’s stem cells are low. Banking cord blood does not guarantee that treatment will be effective and only a treating physi7cian can determine when it can be used.
Umbilical Cord Blood: Information for Childbirth Educators; Renece Waller-Wise, The Journal of Perinatal Education, 20(1), 54–60; Cord Blood Registry | Parent’s Guide to Cord Blood, July 19 2017; Cord Blood and the FDA – Parent’s Guide to Cord Blood, March 11 , 2016
Transplant outcomes are better with related cord blood donor cells compared with unrelated cord blood or bone marrow donor cells.
Gluckman E, Rocha V, Boyer-Chammard A, et al. For the Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337:373-381.
Hematopoietic cell transplantation (HCT) of umbilical cord origin can benefit for malignant and nonmalignant diseases like Fanconi’s anemia, aplastic anemia, leukemias, bone marrow failure syndromes, inborn error of metabolism, congenital disorders and hemoglobinopathies
Diseases Treatable with Cord Blood Transplant
Blood cell proliferation disorders
Hassall, O. W., Thitiri, J., Fegan, G., Hamid, F., Mwarumba, S., Denje, D., … Bates, I. (2015). Safety and efficacy of allogeneic umbilical cord red blood cell transfusion for children with severe anaemia in a Kenyan hospital: an open-label single-arm trial. The Lancet. Haematology, 2(3), e101–e107.
Prasad, V., & Kurtzberg, J. (2009). Umbilical cord blood transplantation for non-malignant diseases. Bone Marrow Transplantation, 44(10), 643-651.
Inherited Immune System Disorders
Chediak-Higashi Syndrome, Chronic Granulomatous Disease, Neutrophil Actin Deficiency, Reticular Dysgenesis
Bhattacharya, A., Slatter, M., Curtis, A., Chapman, C., Barge, D., Jackson, A., Flood, T., Abinun, M., Cant, A. and Gennery, A. (2003). Successful umbilical cord blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplantation, 31(5), pp.403-405.
Reubsaet, L., Boelens, J., Rademaker, C., Smal, J. and Wulffraat, N. (2007). Successful cord blood transplantation in a premature and dysmature neonate of 1700 g with reticular dysgenesis. Bone Marrow Transplantation, 39(5), pp.307-308.
Zhang, Y., Gao, Z. and Yu, X. (2017). A case of Chediak-Higashi syndrome presented with accelerated phase could be treated effectively by unrelated cord blood transplantation. Pediatric Transplantation, p.e13014
Bone Marrow Cancers
Multiple Myeloma, Plasma Cell Leukemia, Waldenstrom’s Macroglobulinemi
Kawamura, K., Takamatsu, H., Ikeda, T., Komatsu, T., Aotsuka, N., Amano, I., Yamamoto, G., Watanabe, K., Ohno, Y., Matsue, K., Kouzai, Y., Tsukada, N., Ishiyama, K., Anzai, N., Kato, K., Suzuki, R., Sunami, K. and Kanda, Y. (2015). Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 21(7), pp.1291-1298.
Inherited Disorders of the Immune System & Other Organs
Cartilage-Hair Hypoplasia, Erythropoietic Porphyria, Hermansky-Pudlak Syndrome, Pearson’s Syndrome, Shwachman-Diamond Syndrome, Systemic Mastocytosis
Allewelt, H., Patel, S., Prasad, V., Kurtzberg, J., Driscoll, T., Martin, P., Page, K. and Parikh, S. (2016). Umbilical Cord Blood Transplantation for Cartilage Hair Hypoplasia: A Single Center Experience Demonstrates Excellent Outcomes Using Myeloablative Preparative Regimens. Biology of Blood and Marrow Transplantation, 22(3), p.S235.
Inherited Metabolic Disorders
Other References for Clinical Trials
CBR Clinical Trials and Stem Cell Research”. cordblood.com. CBR Systems, Inc. Retrieved 21 January 2014.
Cord Blood Registry | Parent’s Guide to Cord Blood, July 19 2017
Cord Blood and the FDA – Parent’s Guide to Cord Blood, March 11, 2016
National Cord Blood Program, 2015
National Marrow Donor Program 3 August 2011
Clinical Trials 3 August 2011
MedicineNet, 2012. Definition of Clinical Trials, 1 February 2014
Clinical trial registry page. ClinicalTrials.gov. Accessed Dec 2015.
Blood Sample from mother
http://www.nationalcordbloodprogram.org/work/collections.html Accessed July 25, 2017